H
ereditary complement deficiencies are usually associated with increased susceptibility to infections and/ or autoimmune diseases. Generally, they are rare: the majority have been detected in no more than a few dozen individuals. However, due to lack of population-based studies, such cases are usually detected by chance, e.g., in severely ill persons and their family members. An exception is mannan-binding lectin (MBL) deficiency, affecting perhaps 5%-10% of the population. MBL, like collectin-10, -11 and the ficolins (M-, L-, H-), is a pattern-recognition molecule, cooperating with MBLassociated serine proteases (MASPs) in the initiation of complement activation via the lectin pathway. In contrast, deficiency of other factors of the lectin pathway seems to be very rare.
Within the MASP family, three proteases (MASP-1, MASP-2, MASP-3) and two related, non-enzymatic proteins, MAp19 (sMAP) and MAp44 (MAP-1), have been identified. MASP-1, MASP-3 and MAp44 are the products of alternative splicing of the MASP1/3 gene while MASP-2 and MAp19 are synthesized under the control of the MASP2 gene. MASP-2 is responsible for activation of complement factors C4 and C2. MASP-2 is composed of six domains: CUB1, EGF, CUB2, CCP1, CCP2 and the serine protease domain. 1 It leads to an exchange of aspartic acid for glycine at residue 120 in the CUB1 domain, 2 resulting in a reduced serum level of MASP-2 and MAp19. The main consequence of the G/G genotype is, however, in preventing formation of complexes with lectins 2 (as the collagen-binding sites are located in the CUB1-EGF-CUB2 domains). Thus, G/G homozygotes are practically unable to activate the lectin pathway of complement. Although perhaps .10% individuals within Caucasian populations may be heterozygous, the frequency of total MASP-2 deficiency has been estimated as 6/10 000.
1 The cases of MASP-2 deficiency first described suggested clear disease associations; 2,3 however, several later reports revealed G/G genotype carriers among healthy controls as well. [4] [5] [6] [7] Totally, homozygosity for the p.D120G mutation has been found in eight patients suffering from various diseases and six healthy controls (Table 1B) .
We report three other instances of MASP-2 deficiency-two in persons with pulmonary tuberculosis (among 440 tested) and one in a perfectly healthy individual (Table 1A) . One of the patients was a 72-year-old male, diagnosed also with chronic obstructive pulmonary disease and angina pectoris. He was infected with a strain of Mycobacterium tuberculosis resistant to streptomycin, isoniazid and ethambutol. The other tuberculosis patient was a 36-year-old woman without any comorbidities. No case of tuberculosis was found among their closest relatives. Moreover, among All three subjects had low MASP-2 concentrations and low MBL-MASP-2 complex activities (Table 1A) . Additionally, one of the tuberculosis patients had a MBL2 gene mutation, at codon 54 of the exon 1 (B variant allele), affecting both MBL serum concentration and activity (Table 1A) . Two cases of MASP-2 deficiency previously reported by us were a 12-year-old boy with recurrent pneumonias and a 4-year-old girl with recurrence of upper respiratory infections and skin abscesses. 3, 8 Detailed diagnostics (both were patients of the Unit of Immunodisorders) showed no other immune abnormalities. They had LYA/LXA and HYA/LXA MBL2 genotypes with serum MBL concentrations of 1.4 mg/ml and 1.8 mg/ml, respectively, while MBL-MASP-2 complex activity was undetectable. 3, 8 Taking into account our experiences as well as data published by others (Table 1) , it might be suspected that MASP-2 deficiency is mainly associated with respiratory disease and/or certain types of cancer. However, as seven examples have been found in healthy controls (compared with 10 patients with serious diseases), it equally might be disease modifier, potentially important when accompanied by other factors, as suggested by Thiel et al.
1 and Olszowski et al. 7 Thus, the clinical impact of MASP-2 deficiency remains uncertain.
Another issue is the frequency of the G/ G genotype. It was originally estimated as six cases per 10 000 individuals. However, more recent data from healthy controls: two cases per 868 (frequency: 0.0023), 4 2/1447 (0.0014), 5 1/596 (0.0017), 6 1/164 (0.0061) 9 or 1/276 (0.0036, this investigation) suggest that MASP-2 deficiency may be commoner than previously thought. Abbreviations: MASP, mannan-binding lectin-associated serine protease; MBL, mannan-binding lectin. a Average (median) values among Polish healthy adults: 375 ng/ml (MASP-2 concentration; n5164); 877 ng/ml (MBL concentration; n5394); 383 mU/ ml (MBL-MASP-2 activity; n5265); 354 mU/ml (MBL-MASP-1 activity; n5260) (unpublished). b Values corresponding to the fifth percentile of Polish healthy adults: 171 ng/ml (MASP-2 concentration); 62 mU/ml (MBL-MASP-2 activity). c One case identified for the first time.
